Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies

NCT05094804 is registered in ClinicalTrials.gov with OncoResponse, Inc. as lead sponsor.

NCT NCT05094804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05094804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents in Subjects With Advanced Malignancies
Lead sponsor
OncoResponse, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
September 9, 2021
Completion date
August 15, 2024
Enrollment
172 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, cancer, head and neck squamous cell carcinoma, leiomyosarcoma, liposarcoma, malignant neoplasm, melanoma, metastatic cancer, non small cell lung cancer, tumor, solid